Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Measured by its binding ability in a functional ELISA.Immobilized human VEGF-C at 10 µg/mL (100 ?l/well) can bind human VEGFR3-his. The EC50 of human VEGFR3-his is 0.011 µg/mL. Measured by its ability to bind human VEGF-D in a functional ELISA.
Endotoxin:
<1.0 EU per µg as determined by the LAL method.
Protein Construction:
A DNA sequence encoding the extracellular domain (Met 1-Ile 776) of human VEGFR3 (NP_002011.2) was expressed with a C-terminal polyhistidine tag.
Purity:
> 97 % as determined by reducing SDS-PAGE.
Mol Mass:
86 kDa
AP Mol Mass:
130 kDa
Formulation:
Lyophilized from sterile PBS, pH 7.4
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Stability and Storage:
Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
